AN2 Therapeutics Inc (NASDAQ:ANTX) has voluntarily paused Phase 3 enrollment in the Phase 2/3 trial (EBO-301) evaluating epetraborole in treatment-refractory Mycobacterium Avium Complex (MAC) lung ...

Researchers at the Jacobs School of Medicine and Biomedical Sciences have developed a new inhalable form of tuberculosis (TB) treatment that could significantly reduce the burden of current therapy.

A multinational European study provides the first comprehensive clinical and genomic data on the Mycobacterium avium complex from continental Europe. The data reveal the population structure of this ...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious ...

Avian tuberculosis, also known as mycobacterium avium complex (MAC) or MAC lung disease, is a respiratory illness. It can lead to symptoms such as chronic cough, shortness of breath, and weight loss.